Blog
Valuable TargetsAdvanced Tech.
Recent blog posts
Obicetrapib/Ezetimibe Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Obicetrapib/Ezetimibe Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Obicetrapib/Ezetimibe: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Piclidenoson Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Piclidenoson Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Piclidenoson: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Balstilimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Balstilimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Balstilimab: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Annamycin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Annamycin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Annamycin: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Compound aluminum sulfate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Compound aluminum sulfate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Compound aluminum sulfate: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Cefilavancin Trihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Cefilavancin Trihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Cefilavancin Trihydrochloride: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Zeleciment Basivarsen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Zeleciment Basivarsen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Zeleciment Basivarsen: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Sintilimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Sintilimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sintilimab, a antibody targeting PD-1.
Read →
Mirodenafil dihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Mirodenafil dihydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Mirodenafil dihydrochloride: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Read →
Toripalimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
Latest Hotspot
6 min read
Toripalimab Biologics Sequence Review Report 2026: PD-1 Similarity and Patent-Risk Signals
21 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Toripalimab, a antibody targeting PD-1.
Read →
Cupabimod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Cupabimod Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Cupabimod: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →
Onvuzosiran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
Latest Hotspot
8 min read
Onvuzosiran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Onvuzosiran: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Read →